Shark-inspired drug may help treat fatal lung disease

Image
Press Trust of India Melbourne
Last Updated : Jan 30 2017 | 4:48 PM IST
A drug that mimics part of a shark's immune system may help treat an incurable lung disease, Australian scientists claim.
Pulmonary fibrosis scars lung tissue, causing breathing to become progressively difficult.
Scientists from La Trobe University in Australia are preparing to run a world-first clinical trial of the new drug inspired by shark antibodies.
The drug, AD-114, is a human protein that is based on the shape of an antibody of a Wobbegong shark.
Recent tests on mouse models found AD-114 led to a reduction in fibrosis in the lung and liver, after treatment for 14 and 21 days respectively.
Scientists at La Trobe and biotechnology company AdAlta created a humanised version of the shark protein called the i-body, and identified a lead therapeutic i-body candidate for the treatment of fibrosis.
"We believe that AD-114 has the potential to be a new treatment for pulmonary fibrosis, a respiratory disease which results in scarring of the lung tissues," AdAlta CEO Sam Cobb said.
"Current therapies for pulmonary fibrosis are considered sub-optimal and there is a high-unmet medical need.
"AD-114 now has strong pre-clinical results for pulmonary fibrosis, demonstrating both anti-fibrotic and anti-inflammatory activity in human lung tissue and indicating greater efficacy than existing approved drugs used to treat the disease," said Cobb.
"The drug's anti-inflammatory and anti-fibrotic properties are effective in reducing collagen build-up in the lungs, which cause shortness of breath in sufferers and eventual death.
"There is great demand for a treatment as current lung fibrosis drugs have proved to have little impact in treating the disease for which there is no cure," Cobb said.
"To the average person sharks are a creature to steer clear of, but in the scientific world treatments based on shark antibody have the potential to save lives," Mick Foley, Associate Professor at La Trobe's Institute of Molecular Science (LIMS) said.
"In the future we think the humanised i-body, AD-114, may also be a suitable drug to treat other forms of fibrosis found in the liver, skin, eyes, heart and kidneys," said Foley.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jan 30 2017 | 4:48 PM IST

Next Story